Skip to content
ClinCalc Pro
Menu
Bulk-Forming Laxative Pregnancy: There is a limited amount of data (less than 300 pregnancy outcomes) from use in pregnant women, and animal studies are insufficient with respect to reproductive toxicity. The use of ispaghula husk may be considered during pregnancy and lactation, if necessary and if change of nutrition is not successful; bulk-forming laxatives should be used before other purgatives. Fertility: no known effects.

Ispaghula Husk

Brand names: Fybogel, Metamucil, Regulan

Ispaghula husk (psyllium) is a bulk-forming laxative used in the management of constipation and to maintain regular bowel function, including in conditions where a softer, bulkier stool is helpful.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: One sachet, morning and evening
Route: Oral — intended for oral use as a suspension in a drink of water. The granules should be stirred into a glass of water and taken as soon as possible, preferably after meals. The product should NOT be taken dry and should always be taken mixed with fluid (5 fluid ounces or 150 mL of water or other liquid per sachet).
Frequency: Twice daily (morning and evening)
Source: eMC SPC for Fybogel Hi-Fibre Lemon Granules (ispaghula husk sachets). No maximum dose is stated in the source. ONSET: 'The effect start 12-24hours later.' TIMING: the product should be taken during the day at least half an hour to 1 hour before or after intake of other medicines, and should not be taken immediately before going to sleep (impaired or reduced gastric motility may impair intestinal passage and cause sub-obstruction). DURATION: if there have been no bowel movements after three days of treatment, a doctor or healthcare professional should be consulted. ELDERLY: 'There is no indication that dosage needs to be modified for the elderly'; however, treatment of debilitated and/or elderly patients requires medical supervision. PAEDIATRIC (no per-kg dose is stated, so no structured paedDose has been recorded): children over 12 years — one sachet, morning and evening; children aged 6 to 12 years — half to one level 5 mL spoonful depending on size and age, morning and evening; children under 6 years — use is not recommended due to insufficient data on safety and efficacy. Verify against a children's formulary. PREPARATION: when preparing the product it is important to try to avoid inhaling any of the powder, in order to minimise the risk of sensitisation to the active ingredient; occupational contact with the powder may cause allergic sensitisation by inhalation, more frequently in atopic individuals. EXCIPIENTS: contains 16 mg aspartame per sachet (a source of phenylalanine — may be harmful in phenylketonuria); less than 1 mmol sodium (23 mg) per sachet, i.e. essentially sodium-free; 0.25 mmol (9.76 mg) potassium per sachet, to be taken into consideration by patients with reduced kidney function or on a controlled potassium diet.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to ispaghula husk or to any of the excipients
  • Patients with a sudden change in bowel habit that has persisted more than two weeks
  • Undiagnosed rectal bleeding, and failure to defecate following the use of a laxative
  • Abnormal constrictions in the gastro-intestinal tract, diseases of the oesophagus and cardia, intestinal obstruction, faecal impaction, natural or drug-induced reduction of gut motility, and colonic atony such as senile mega-colon
  • Patients who have difficulty in swallowing or any throat problems

Side effects

  • Hypersensitivity disorders (frequency not known), including rash, anaphylaxis, pruritus and bronchospasm
  • Flatulence and abdominal distension (frequency not known) — a small amount may occur during the first few days of treatment but should diminish with continued treatment
  • Intestinal obstruction, oesophageal obstruction and faecal impaction (frequency not known), particularly if swallowed with insufficient fluid; symptoms can be chest pain, vomiting, or difficulty in swallowing or breathing
  • Conjunctivitis and rhinitis (frequency not known), reflecting the allergenic potential of ispaghula/psyllium husk
  • Skin rash (frequency not known)

Interactions

  • Should not be used together with medicinal products known to inhibit peristaltic movement (e.g. opioids), in order to decrease the risk of gastrointestinal obstruction — and then only under medical supervision (from §4.4)
  • Enteral absorption of concomitantly administered medicines may be affected — the SPC directs that the product be taken at least half an hour to 1 hour before or after other medicines. NOTE: §4.5 itself is cut off mid-sentence ('Enteral absorption of …') in this bundle, so the full UK interaction list has not been retrieved — clinician to source it

Clinical monograph

How it works

Its soluble fibre absorbs water in the gut to increase faecal mass, which stimulates peristalsis and softens the stool.

Prescribing in practice

  • Take with plenty of fluid and avoid taking immediately before going to bed, as inadequate fluid intake risks intestinal or oesophageal obstruction and impaction.
  • It is contraindicated in intestinal obstruction, faecal impaction and conditions such as colonic atony where bulking agents are inappropriate.
  • Full effect develops gradually over days, so it is not suitable for rapid relief of acute constipation.

Monitoring

Routine laboratory monitoring is not required; review the bowel response and ensure adequate fluid intake is maintained.

Counselling the patient

  • Mix the dose with plenty of water and drink it straight away, and keep your fluid intake up during the day.
  • Do not take it just before lying down or going to bed.

Evidence & guidelines

Bulk-forming laxatives such as ispaghula are recommended as a first-line option for constipation in line with NICE guidance.

Reference: NICE CG61 Irritable Bowel Syndrome; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.